Reference | CSTD | Costs | Cost savings | CHEERS criteria | Limitations | ||
Type | Values | Type | Values | ||||
Ozyaman (2016) Turkey19 | PhaSeal (compared with conventional system) | Not evaluated | Not evaluated | Extension of BUD | €36 137/ 3 months | NA | Acquisition costs not evaluated. Partial data reported (as a poster). |
Kicenuik et al (2017) USA23 | Equashield PhaSeal (compared with conventional system) | Acquisition costs, administration time | Equashield: US$15.73/dose 24 s/dose PhaSeal: US$24.09/dose 29.1 s/dose Conventional: 26.9 s/dose | Not evaluated | Not evaluated | 12/24 | Phaseal sold by the unit and Equashield sold in bulk. Simulated administrations. Acquisition costs not evaluated for conventional system. Conflicts of interest: CSTDs provided free of charge by the manufacturers. |
BUD, beyond-use date; CHEERS, Consolidated Health Economic Evaluation Reporting Standards; CSTD, closed system transfer device; NA, not applicable.